EN | TR
E-ISSN: 2651-2661 ISSN: 2651-2653
Real life data of secukinumab in ankylosing spondylitis and psoriatic arthritis: Analysis of 44 patients in a single center
PDF
Cite
Share
Request
Original Article
VOLUME: 13 ISSUE: 3
P: 116-120
December 2021

Real life data of secukinumab in ankylosing spondylitis and psoriatic arthritis: Analysis of 44 patients in a single center

J Turk Soc Rheumatol 2021;13(3):116-120
DOI: 10.4274/raed.galenos.2021.35745
Murat Bektaş 1
Çiğdem Çetin 1
Çağrı Burak Uğurlu 2
Fatih Kemik 2
Ahmet Can Çiftçi 2
Yasemin Yalçınkaya 1
Bahar Artım Esen 1
Mahdume Lale Öçal 1
Ahmet Gül 1
Murat İnanç 1
1. İstanbul Üniversitesi-İstanbul Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, İstanbul, Türkiye
2. İstanbul Üniversitesi-İstanbul Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, İstanbul, Türkiye
No information available.
No information available
Received Date: 07.09.2021
Accepted Date: 11.11.2021
Publish Date: 22.12.2021
PDF
Cite
Share
Request

ABSTRACT

Conclusion:

Secukinumab appears to be a safe and effective treatment option in selected patients with treatment naive to anti- TNFs or in patients with AS and PsA who could not use it due to unresponsiveness and/or intolerance.

Results:

The mean age of patients was 44.9 years and most of them were male (61.4%). Secukinumab treatment was initiated in 33 AS (75%) and 11 (25%) PsA patients. The mean duration of secukinumab treatment was 9.1±5.3 months in AS and 7.0±4.0 months in PsA. The continuation rate of secukinumab was 75.7% (n=25) in AS and 63.6% (n=7) in PsA. No severe infection or malignancy development was observed during secukinumab treatment in the follow-up period.

Methods:

Forty-four patients were included in the study with the diagnosis of AS and PsA. Secukinumab treatment was started between May 2018 and October 2019, and their data were analyzed retrospectively.

Objective:

Secukunimab is a fully human monoclonal antibody to IgG1-kappa that binds to IL-17A and its long-term data are well known. However, real-life data on treatment outcomes are limited in our country. In our study, we aimed to evaluate the early results of secukinumab, which is relatively newly used in our country, in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA), who were followed up in our clinic.

References

1Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017;390:73-84.
2Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. Drugs 2002;62:2447-57.
3Glintborg B, Ostergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382-90.
4Dubash S, McGonagle D, Marzo-Ortega H. New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. Ther Adv Chronic Dis 2018;9:77-87.
5Torgutalp M, Poddubnyy D. Emerging treatment options for spondyloarthritis. Best Pract Res Clin Rheumatol 2018;32:472-84.
6Paine A, Ritchlin CT. Targeting the interleukin-23/17 axis in axial spondyloarthritis. Current opinion in rheumatology 2016;28:359-67.
7Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 2017;76:1070-7.
8Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 2019;21:111.
9Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 2005;64:188-90.
10Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis 2011;70:2152-4.
11Mease PJ, Karki C, Palmer JB, et al. Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Care Res (Hoboken) 2017;69:1692-9.
12Gladman DD, Ziouzina O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol 2013;40:1357-9.
13Micheroli R, Tellenbach C, Scherer A, et al. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. Ann Rheum Dis 2020;79:1203-9.
14Michelsen B, Lindström U, Codreanu C, et al. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD open 2020;6.
15Blair HA, Dhillon S. Secukinumab: A Review in Ankylosing Spondylitis. Drugs 2016;76:1023-30.
16Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis 2017;76:571-92.
17Glintborg B, Lindstrom U, Di Giuseppe D, et al. One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in Spondyloarthritis. Arthritis Care Res (Hoboken) 2020.
18Baraliakos X, Kivitz AJ, Deodhar AA, et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol 2018;36:50-5.
19Braun J, Baraliakos X, Deodhar A, et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology (Oxford) 2019;58:859-68.
20Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD open 2017;3:e000592.
21Deodhar AA, Miceli-Richard C, Baraliakos X, et al. Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. ACR open rheumatology 2020;2:294-9.
22Wang J, Bhatia A, Krugliak Cleveland N, et al. Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion. ACG case reports journal 2018;5:e56.
23Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis 2019;78:473-9.
24Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013;120:777-87.
Article is only available in PDF format. Show PDF
2024 ©️ Galenos Publishing House